http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15923805

Am J Clin Oncol. 2005 Jun;28(3):301-9.

http://www.amjclinicaloncology.com/pt/re/ajco/abstract.00000421-200506000-00015.htm

Long-term follow up of high-dose chemotherapy with autologous stem cell
rescue in adults with Ewing tumor.

Laurence V, Pierga JY, Barthier S, Babinet A, Alapetite C, Palangie T,
de Pinieux G, Anract P, Pouillart P.

Department of Medical Oncology, Institut Curie, Paris, France.

Ewing tumors remain of poor prognosis, with 5-year overall survival of
55% to 65% in localized patients and not exceeding 25% in primarily
metastatic disease. Several reports, mainly in children, have reported
that some patients with poor-risk Ewing tumors may benefit from
high-dose chemotherapy (HDCT) with autologous stem cell rescue. This
retrospective study analyzed 46 patients treated in our institution
between 1987 and 2000 for localized or primary metastatic Ewing tumors
by HDCT followed by stem cell rescue. Median follow up was 7.1 years.
Median age was 21 years (range, 15-46 years). Twenty-two percent of
patients had metastases at diagnosis. The tumor site was axial in 56% of
patients. Median tumor size was 9.5 cm. The treatment regimen consisted
of induction chemotherapy, local treatment, maintenance chemotherapy,
and consolidation HDCT based on alkylating agents. No toxic death was
observed in the intensive therapy phase. Five-year overall survival and
progression-free survival were 63 +/- 7.7% and 47 +/- 7.6%,
respectively. Pejorative prognostic factors in this population were
metastases at diagnosis (5-year overall survival 34% vs.71%, P = 0.017)
and poor pathologic response (5-year overall survival 44% vs.77%, P =
0.03). This retrospective study shows a high long-term survival rate
with high-dose chemotherapy in adults.

PMID: 15923805 [PubMed – indexed for MEDLINE]